<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047692</url>
  </required_header>
  <id_info>
    <org_study_id>AdCLD-CoV19-1-001</org_study_id>
    <nct_id>NCT05047692</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers</brief_title>
  <official_title>A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellid Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cellid Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 clinical trial to assess the safety and immunogenicity of AdCLD-CoV19-1 in&#xD;
      healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose-escalation, multi-center, open-label, Phase 1 clinical trial. We assess the&#xD;
      safety of AdCLD-CoV19-1 and immune responses against SARS-CoV-2. DSMB will evaluate safety&#xD;
      when events occurred during the whole study period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of solicited adverse events(AEs)</measure>
    <time_frame>Through 7 days post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of unsolicited AEs</measure>
    <time_frame>Through 28 days post-vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events(SAEs)</measure>
    <time_frame>Through 12 months post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events of special interest(AESIs)</measure>
    <time_frame>Through 12 months post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate(SCR) of neutralization antibody against wild type SARS-CoV-2</measure>
    <time_frame>4 weeks post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer(GMT) of neutralization antibody against wild type SARS-CoV-2</measure>
    <time_frame>4 weeks post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of S protein specific antibody</measure>
    <time_frame>2, 4, 26, 52 weeks post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S protein specific T cell response</measure>
    <time_frame>2, 4, 26, 52 weeks post-vaccination</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>GMT of S protein receptor binding domain(RBD) specific antibody</measure>
    <time_frame>2, 4, 26, 52 weeks post-vaccination</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Group 1: Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subject will receive a single dose of AdCLD-CoV19-1(5.0x10^10VP) as an intramuscular injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subject will receive a single dose of AdCLD-CoV19-1(1.0x10^11VP) as an intramuscular injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AdCLD-CoV19-1</intervention_name>
    <description>Replication deficient adenoviral vector based COVID-19 prevention vaccine containing recombinant gene of SARS-CoV-2 spike protein</description>
    <arm_group_label>Group 1: Low dose</arm_group_label>
    <arm_group_label>Group 2: High dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to agree informed consent and aged 19 to 64 years.&#xD;
&#xD;
          -  The BMI index is 18.5 kg/m2 to 30.0 kg/m2.&#xD;
&#xD;
          -  Able and willing to medically effective contraception during the whole study period.&#xD;
&#xD;
          -  Agreement to refrain from blood donation during the whole study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anyone deemed infected by COVID-19.&#xD;
&#xD;
          -  Determined to be a close-contact of SARS-CoV-2 confirmed case or classified to&#xD;
             symptomatic patient of COVID-19 prior to vaccination.&#xD;
&#xD;
          -  Clinically significant abnormal ranges of laboratory measurement, ECG, Chest X-ray at&#xD;
             screening visit.&#xD;
&#xD;
          -  Positive in HIV, HBV, HCV test at screening visit.&#xD;
&#xD;
          -  Acute fever(≥ 38℃) or suspected infectious disease, symptoms of infectious&#xD;
             disease(cough, difficulty breathing, chills, muscle aches, headache, sore throat, loss&#xD;
             of smell, or loss of taste, etc.) within 3 days prior to vaccination.&#xD;
&#xD;
          -  Chronic respiratory disease: Asthma, chronic obstructive pulmonary disease, active&#xD;
             tuberculosis, latent tuberculosis under treatment.&#xD;
&#xD;
          -  Clinically significant active or any history of disease: Hepatobiliary system, kidney,&#xD;
             central or peripheral nervous system (epilepsy, seizure, etc.), endocrine system&#xD;
             (uncontrolled diabetes, hyperlipidemia, etc.), cardiovascular system (congestive heart&#xD;
             failure, coronary artery disease, myocardial infarction, control Hypertension, etc.),&#xD;
             blood tumor, urinary system, mental, musculoskeletal system, immune system (rheumatoid&#xD;
             arthritis, systemic lupus erythematosus).&#xD;
&#xD;
          -  Immunosuppressive disease including immunodeficiency disease.&#xD;
&#xD;
          -  Scheduled to undergo any surgery during the whole study period.&#xD;
&#xD;
          -  Healthcare worker who provide medical care to SARS-CoV-2 cases or occupationally in&#xD;
             high risk for SARS-CoV-2 exposure during the whole study period.&#xD;
&#xD;
          -  Prisoners or subjects who are compulsorily detained. (involuntary incarceration)&#xD;
&#xD;
          -  History of SARS or MERS.&#xD;
&#xD;
          -  Allergic reaction or hypersensitivity to any ingredient of AdCLD-CoV19-1.&#xD;
&#xD;
          -  Having hemophilia at risk of causing serious bleeding when injected intramuscularly or&#xD;
             receiving anticoagulants.&#xD;
&#xD;
          -  Any history of malignant disease within the past 5 years. History of hypersensitivity&#xD;
             to inoculate vaccine such as Guillain-Barre syndrome.&#xD;
&#xD;
          -  History of serious adverse reaction or allergic reaction to inoculate vaccine.&#xD;
&#xD;
          -  Urticaria past 5 years prior to vaccination.&#xD;
&#xD;
          -  History of hereditary angioneurotic edema or acquired angioneurotic edema.&#xD;
&#xD;
          -  History of solid organ or bone marrow transplantation.&#xD;
&#xD;
          -  Suspected or a history of drug or alcohol abuse past 12 month before vaccination.&#xD;
&#xD;
          -  Receipt of vaccine of SARS-CoV, MERS-CoV, SARS-CoV-2.&#xD;
&#xD;
          -  Receipt of adenovirus vector based vaccine.&#xD;
&#xD;
          -  Chronic use of immunosuppressant or immune modifying drug within 6 months prior to&#xD;
             vaccination. (use of inhaled, topical, nasal, and ophthalmic corticosteroids are&#xD;
             allowed)&#xD;
&#xD;
          -  Having relied on antipsychotic drugs and narcotic analgesics within 6 months before&#xD;
             vaccination or difficult to comply with the clinical trial procedure at the judgment&#xD;
             of the investigator.&#xD;
&#xD;
          -  Administered to other investigational product or medical device within 6 months before&#xD;
             vaccination.&#xD;
&#xD;
          -  Other vaccination history within 30 days prior to vaccination or being scheduled&#xD;
             within 30 days after vaccination.&#xD;
&#xD;
          -  Receipt of immunoglobulin or any blood product within 3 month prior to vaccination.&#xD;
&#xD;
          -  Pregnant(including positive hCG test at screening visit) or breastfeeding female.&#xD;
&#xD;
          -  Those who are directly related to the investigator.&#xD;
&#xD;
          -  Other condition deemed ineligible for the study at the discretion of investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gaeun Park, M.S</last_name>
    <phone>+82-3285-7863</phone>
    <email>gepark@cellid.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wuhyun Kim, DVM</last_name>
    <phone>+82-3285-7863</phone>
    <email>whkim@cellid.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <state>Province</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, ST. Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Province</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>State</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaeun Park, M.S</last_name>
      <email>gepark@cellid.co.kr</email>
    </contact>
    <investigator>
      <last_name>Heejin Cheng, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Prevention</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

